Financial Market News and Analysis

Space Exploration Technologies Corp. aka SpaceX delivered a spectacular Q2, with $7.81B in revenue and $3.54B in adjusted EBITDA, beating expectations across nearly every major business line. Yet SPCX stock fell about 8% after earnings. Investors were not questioning the growth; they were questioning how much capital SpaceX must spend to produce it. Starlink remains the economic engine of the group, generating $4.29B in revenue and $1.66B in operating profit while AI and Space posted combined operating losses of roughly $1.80B.

Related Symbols 1

S SPCX SPCX

Source: Seeking Alpha

Visit Source

0 0 0

Comment

Source: WSJ News Agency

1 month ago

Stock Medium Importance

Disney to Sell Its Stake in A+E Global Media to Hearst for About $1.2 Billion

The deal will give Hearst full ownership of prominent brands such as Lifetime and The History Channel.

Related Symbols 1

G GTLL GTLL

Source: WSJ

Visit Source

0 0 0

Comment

Source: Zacks Investment Research News Agency

1 month ago

Stock Medium Importance

Syndax Pharmaceuticals (SNDX) Reports Q2 Loss, Lags Revenue Estimates

Syndax Pharmaceuticals (SNDX) came out with a quarterly loss of $0.55 per share versus the Zacks Consensus Estimate of a loss of $0.45. This compares to a loss of $0.83 per share a year ago.

Related Symbols 1

S SNDX SNDX

Source: Zacks Investment Research

Visit Source

0 0 0

Comment

Source: Zacks Investment Research News Agency

1 month ago

Stock Medium Importance

Rigel Pharmaceuticals (RIGL) Q2 Earnings Miss Estimates

Rigel Pharmaceuticals (RIGL) came out with quarterly earnings of $0.88 per share, missing the Zacks Consensus Estimate of $0.91 per share. This compares to earnings of $3.28 per share a year ago.

Related Symbols 1

R RIGL RIGL

Source: Zacks Investment Research

Visit Source

Official Partner ITBFX Start Trading

0 0 0

Comment

Source: Zacks Investment Research News Agency

1 month ago

Stock Medium Importance

Personalis (PSNL) Reports Q2 Loss, Tops Revenue Estimates

Personalis (PSNL) came out with a quarterly loss of $0.3 per share versus the Zacks Consensus Estimate of a loss of $0.25. This compares to a loss of $0.23 per share a year ago.

Related Symbols 1

P PSNL PSNL

Source: Zacks Investment Research

Visit Source

0 0 0

Comment

Source: Zacks Investment Research News Agency

1 month ago

Stock Medium Importance

Lumen (LUMN) Reports Q2 Loss, Tops Revenue Estimates

Lumen (LUMN) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to a loss of $0.03 per share a year ago.

Related Symbols 1

L LUMN LUMN

Source: Zacks Investment Research

Visit Source

0 0 0

Comment

Source: Zacks Investment Research News Agency

1 month ago

Stock Medium Importance

Allegiant Travel (ALGT) Q2 Earnings Beat Estimates

Allegiant Travel (ALGT) came out with quarterly earnings of $2.19 per share, beating the Zacks Consensus Estimate of $1.27 per share. This compares to earnings of $1.23 per share a year ago.

Related Symbols 1

A ALGT ALGT

Source: Zacks Investment Research

Visit Source

0 0 0

Comment

Source: Zacks Investment Research News Agency

1 month ago

Stock Medium Importance

Gilead Sciences (GILD) Reports Q2 Loss, Beats Revenue Estimates

Gilead Sciences (GILD) came out with a quarterly loss of $6.75 per share versus the Zacks Consensus Estimate of a loss of $7.07. This compares to earnings of $2.01 per share a year ago.

Related Symbols 1

G GILD GILD

Source: Zacks Investment Research

Visit Source

0 0 0

Comment

Source: Zacks Investment Research News Agency

1 month ago

Stock Medium Importance

Amgen (AMGN) Q2 Earnings and Revenues Surpass Estimates

Amgen (AMGN) came out with quarterly earnings of $6.29 per share, beating the Zacks Consensus Estimate of $5.6 per share. This compares to earnings of $6.02 per share a year ago.

Related Symbols 1

A AMGN AMGN

Source: Zacks Investment Research

Visit Source

0 0 0

Comment

Source: Zacks Investment Research News Agency

1 month ago

Stock Medium Importance

Travere Therapeutics (TVTX) Reports Q2 Loss, Beats Revenue Estimates

Travere Therapeutics (TVTX) came out with a quarterly loss of $0.37 per share versus the Zacks Consensus Estimate of a loss of $0.14. This compares to a loss of $0.14 per share a year ago.

Related Symbols 1

T TVTX TVTX

Source: Zacks Investment Research

Visit Source

0 0 0

Comment